Damora Therapeutics
DMRA
19 hedge funds and large institutions have $82.9M invested in Damora Therapeutics in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
1.64% less ownership
Funds ownership: 55.85% → 54.21% (-1.6%)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
53% less capital invested
Capital invested by funds: $175M → $82.9M (-$91.7M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$612K |
| 2 |
Goldman Sachs
New York
|
+$146K |
| 3 |
Millennium Management
New York
|
+$140K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$4.9K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$544 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$2.44M |
| 2 |
BlackRock
New York
|
-$1.26M |
| 3 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.05M |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$272K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$250K |
DMRA Hedge Fund Activity: Q1 2021 in Review
19 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q1 2021, worth a combined $82.9M — down 53% from $175M a quarter earlier.
Fund positioning in DMRA was balanced in Q1 2021: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 6 trimmed.
The largest buyer was Sphera Funds Management, adding an estimated $612K. The largest seller was Asymmetry Capital Management, cutting an estimated $2.44M.
- 19 institutional investors held Damora Therapeutics (DMRA) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $82.9M of Damora Therapeutics stock for Q1 2021, down 53% quarter-over-quarter.
- 3 funds opened new Damora Therapeutics positions in Q1 2021 and 3 closed out, a net change of 0 holders.
- The largest Damora Therapeutics buyer in Q1 2021 was Sphera Funds Management, an estimated $612K added.
- The largest Damora Therapeutics seller in Q1 2021 was Asymmetry Capital Management, an estimated $2.44M sold.
Based on aggregated 13F filings for Q1 2021.